Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Pathos logo — AI-enabled drug development built for patients

Pathos

AI-enabled drug development built for patients

Founded 2022 United States Chicago, United States 96 employees Series D Total: $365.00M

General Information

Company Name Pathos
Founded Year 2022
Location United States Chicago, United States +1
Employees 96
Funding Stage Series D
Social

Get notified when Pathos moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Pathos recently secured a substantial $283M Series D funding round in May 2025, demonstrating significant investor confidence and providing ample capital runway. This major capital infusion is now translating into accelerated operational expansion, evidenced by the current recruitment for 13 new positions, signaling a strategic push to scale its team and advance its AI-enabled precision oncology programs.

Signal Types
Funding Hiring
Strategic Labels
Capital Infusion Team Expansion R&D Acceleration
Next Move: Expansion
·
Impact: 9/10
·
Ideal For: Growth Equity VCs – Clinical-stage Biotech

About Pathos

Pathos, founded in 2022 and headquartered in the United States, is a clinical-stage, AI-enabled precision oncology biotech. Its slogan, "AI-enabled drug development built for patients", encapsulates its mission to revolutionize the biopharma sector.

The company is pioneering the integration of AI with multimodal patient data to innovate drug development processes. Utilizing the largest Multimodal Foundation Model in Oncology, Pathos operates an advanced engine that aligns model-driven hypotheses with biological validation and biomarker-centric clinical execution. This strategy aims to expedite the delivery of targeted therapies to patients, significantly improving patient outcomes.

In a noteworthy achievement, Pathos secured a substantial $283.00 million in Series D investment on 01 May 2025. This infusion of capital underlines investor confidence in its cutting-edge approach to oncological therapies. The company's innovative blend of technology and biology positions it as a promising leader in the future of drug development.

Taxonomy: AI-enabled Drug Development, Precision Oncology, Multimodal Patient Data, Oncology, Biomarker-driven Clinical Execution, Clinical Trials, Drug Discovery, Cancer Biology, Computational Biology, Biopharma, Model-driven Hypotheses, Precision Medicine

Services & Products

AI-driven Clinical Trials
Precision Therapy Discovery
Data Modeling for Oncology
Biopharmaceutical Collaboration

Target Customers

Biopharmaceutical Companies Clinical Researchers Healthcare Providers Investors in Biotech

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series D •••••• - 01 May 2025
Series C •••••• 4
Investor Investor Investor Investor
01 Oct 2024
Late Vc •••••• - 01 Mar 2023

Pathos Alternatives & Competitors

View All Alternatives
Pathos vs
Cancer Therapy Advisor
Cancer Therapy Advisor United States

Comprehensive knowledge base of practical oncology information and clinical tools.

1 employees
Health Care, IT
Pathos vs
Cumulus Oncology
Cumulus Oncology United Kingdom

Finding assets, creating spin-outs, commercialising cancer therapies.

16 employees
Pathos vs
Scailyte
Scailyte Switzerland

True precision medicine through single-cell science.

Series A
18 employees
AI, Biotechnology
Compare Pathos vs Scailyte
Also compare with: Pathos vs Molecs Molecs Pathos vs Regor Therapeutics Group Regor Therapeutics Group Pathos vs Acrivon Therapeutics, Inc. Acrivon Therapeutics, Inc. View all alternatives

FAQ About Pathos

AI-enabled drug development built for patients
Pathos was founded in 2022.
Pathos is headquartered in Chicago, United States.
Pathos has approximately 96 employees.
Pathos has completed 3 funding rounds, raising a total of $365.00M. The latest funding stage is Series D.
Pathos offers: AI-driven Clinical Trials, Precision Therapy Discovery, Data Modeling for Oncology, Biopharmaceutical Collaboration.
Top alternatives and competitors to Pathos include Cancer Therapy Advisor, Cumulus Oncology, Scailyte, Oncology Nurse Advisor, Molecs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pathos and Cancer Therapy Advisor are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Pathos and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy